Welcome Packet
Been diagnosed or want to learn more?
Request a Packet
About Duchenne
Facts, Treatment, and Care
Read More
Duchenne News
The latest from our partners.
Read Now
Female Carriers
Resources, Care, and Programs
Community Ambassadors
Meet our Community Ambassadors
Clinical Trials
A quick look at investigational drug studies
Volunteer Opportunities
Ways to get involved and help raise funds and awareness for Duchenne.
Volunteer Today
Community Ambassadors
These ambassadors are Jett Foundation’s extra ears, eyes, and voice.
Toolkits
View our resources targeted toward volunteers.
Our Resources
Become a Partner
Learn about creating a partnership and joining our community.
Get Started
Host a Webinar
Learn about our community webinar series.
View Upcoming Webinars
Resource Library
Read about our resources for Partners.
Resources for Partners
How To Help
Make a difference in the lives of those living with Duchenne.
Get Started Volunteering
Clinical Trials
A quick look at investigational drug studies.
Read More About Clinical Trials
Duchenne News
Stay up to date with the latest discoveries.
Read Now
Book: Dan And DMD
This book will help parents and guardians as they prepare to talk to their children about Duchenne.
Read Here
Our Insurance Flight Plan
Our Health Insurance Flight Plan breaks down options that may be available to you.
Request a Flight Plan
Resource Library
Read about our resources for Medical Professionals.
Resources for Medical Professionals
About Female Carriers
Facts and information about female carriers.
Learn More
Resources for Carriers
Tools and materials for female carriers.
Read More
Connect with our Specialist
Get support and help navigating your journey.
Meet Trina
Carrier Conversations
Join a carrier support group session.
Upcoming Events
General Resources
Check out helpful tools and transition resources.
Find Resources
Transition Resources
GotTransition resources and tools.
Learn More
Camp Promise
Locations and information on how to apply.
Learn More
Community Webinars
Watch past recordings on care and resource topics.
Watch Now
Join Jett Foundation’s Community Webinar Series as we welcome Kelly DiTrapani, Mark Stahl, and Alissa Peters from Avidity Biosciences for a presentation and discussion on a new approach to exon skipping. Avidity plans to advance their first drug development program for Duchenne muscular dystrophy, AOC 1044, into clinical trials by the end of this year.
Kelly DiTrapani, RN, BSN, BA
Vice President, Medical Affairs
Avidity Biosciences
In September of 2020, Kelly DiTrapani joined Avidity as Vice President of Medical Affairs at Avidity Biosciences. Kelly brings extensive commercial and medical affairs leadership in the life sciences industry, focused on bringing innovative therapeutics to patients in the oncology and rare disease spaces including Gleevec, Soliris, and Imbruvica. Throughout her career, Kelly has held positions in industries and academics across roles in research, commercial, and medical affairs at Ortho Biotech (J&J), Novartis Oncology, Duke University, Alexion Pharmaceuticals, Pharmacyclics, Versartis and Iovance Biotherapeutics. Kelly received both her Bachelor of Arts and Bachelor of Science in Nursing from Duke University. Visit Kelly on LinkedIn.
Mark Stahl, MD, PHD
Senior Director, Clinical Development
Avidity Biosciences
Mark Stahl joined Avidity as Senior Medical Director in March of 2021. Most recently, he served as Medical Director in Early Clinical Development at Neurocrine Biosciences, where he worked on multiple pre-clinical and clinical stage programs, including the initiation of new gene therapy programs in rare diseases. Previously, Mark worked as an Assistant Professor at Penn State University, where he founded a research laboratory focused on modeling neurodegenerative diseases, was associate director of the university’s Medical Scientist Training Program, and maintained an active clinical practice in neurology. Mark holds a M.D. degree from the Albert Einstein College of Medicine and completed both residency in neurology and fellowship training in movement disorders at UCLA. He holds a Ph.D. in cell biology, also from the Albert Einstein College of Medicine, and completed his postdoctoral research fellowship training in neuroscience at UCLA. Visit Mark on LinkedIn.
Alissa Peters
Director of Patient Advocacy and Corporate Affairs
Avidity Biosciences
Alissa joined Avidity Biosciences in June of 2020 and serves as the Director of Patient Advocacy and Corporate Affairs. Alissa has focused her career on supporting the development and commercialization of RNA-targeted therapeutics for rare diseases with high unmet needs. Prior to joining Avidity, Alissa served as Associate Director of Global Marketing, helping bring Tegsedi® to patients living with TTR Amyloidosis with Polyneuropathy, a rare neuromuscular disease which ignited her passion to focus in this therapeutic area. At Avidity, Alissa actively partners with patient and advocacy communities to ensure their perspectives are central across all initiatives at the organization. Alissa is passionate about seeing people’s lives changed through the delivery of new therapeutics. Visit Alissa on LinkedIn.
Our Community Webinar Series is focused on ensuring that our Duchenne community is better prepared for those unexpected moments, challenging medical decisions, and difficult stages when on a Duchenne journey.
No one ever expects Duchenne and there is no correct way to tackle a diagnosis, but we can always better prepare. This webinar series is an opportunity to equip yourself with more knowledge, resources, and tools for those real-life, often unanticipated, scenarios.
Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org
Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*)
Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!
Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.